BlossomHill Therapeutics (NASDAQ:BLSM) Issues Quarterly Earnings Results, Misses Expectations By $0.36 EPS

BlossomHill Therapeutics (NASDAQ:BLSM) announced its earnings results on Thursday. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.36), FiscalAI reports.

BlossomHill Therapeutics Trading Down 7.9%

BLSM traded down $1.28 on Thursday, hitting $14.84. 256,383 shares of the company were exchanged, compared to its average volume of 203,191. BlossomHill Therapeutics has a twelve month low of $11.02 and a twelve month high of $27.99. The stock has a market capitalization of $471.62 million and a P/E ratio of -1.70. The business has a 50-day moving average price of $18.22.

Analysts Set New Price Targets

BLSM has been the subject of several research analyst reports. Leerink Partners raised their price target on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, September 21st. HC Wainwright reiterated a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Wall Street Zen raised BlossomHill Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Lifesci Capital assumed coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 target price for the company. Finally, JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 target price for the company. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

About BlossomHill Therapeutics

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.